When the chemistry that carries medicine into human lungs becomes scarce, the economics of compassion are forced into the open. Cipla, one of India's foremost pharmaceutical manufacturers, has appealed to the National Pharmaceuticals Pricing Authority to permit price increases on asthma and respiratory drugs, after the cost of propellant P227 — the invisible engine inside every metered dose inhaler — surged by roughly 300 percent due to supply shortages. The regulator now holds in its hands a question as old as public health itself: who bears the cost when the systems sustaining essential medi
Cipla Seeks Price Hike for Asthma Drugs Citing 300% Surge in Propellant Costs
Potential impact on asthma and COPD patients if drug prices increase, affecting medication accessibility for vulnerable populations.
The propellant is not incidental; it is the delivery mechanism itself.
Mark
So Cipla is saying their costs went up 300 percent. That's a real number, right? Where does it come from?
Mimi
It comes from Cipla's own letter to the pricing authority. They're citing propellant P227 specifically—the chemical that makes inhalers work. They say manufacturers are scarce and prices have climbed that steeply.
Luke
But we should be careful here. That's Cipla's claim in their request. We don't have independent verification of the 300 percent figure or confirmation from propellant suppliers themselves about what's actually happening in that market.
Mark
Fair point. But the propellant shortage itself—is that real?
Mimi
The letter describes it as a real constraint. After CFCs were phased out, there were only two alternative propellants approved for pharmaceutical use. If supply from manufacturers has tightened, that would create genuine pressure.
Luke
Right, but we don't know from this reporting why supply tightened. Is it a global shortage? A manufacturing issue? A deliberate reduction? The letter doesn't say, and we haven't heard from the propellant makers.
Mark
So what's actually at stake if the NPPA says no to a price increase?
Mimi
Cipla says it can't sustain production at current prices if input costs have truly tripled. That could mean reduced supply or the company prioritizing other products.
Luke
Or it could mean Cipla absorbs some of the cost. We don't know their actual margins or whether they have room to negotiate with suppliers. The letter presents one scenario—that prices must rise—but there are other possibilities.
Mark
And if prices do rise?
Mimi
Millions of asthma patients in India could face higher out-of-pocket costs for medications they need regularly. For people on tight budgets, that's real hardship.
Luke
That's true, but we also don't know how much prices would rise or how many patients would actually be priced out. Those are important details we don't have yet.
The Pulse
- A 300% surge in the cost of propellant P227 has made asthma inhaler production economically unsustainable for Cipla, one of India's largest pharmaceutical manufacturers.
- The shortage is not peripheral — propellants constitute 95 to 99 percent of a metered dose inhaler, functioning as the delivery mechanism that drives medication deep into the lungs.
- With only a handful of manufacturers capable of producing P227 globally, supply tightness has sent prices to what Cipla itself describes as 'astronomical' levels, quadrupling production costs.
- Cipla's formal appeal now rests with the NPPA, the government body tasked with balancing manufacturer viability against patient affordability — a tension with no easy resolution.
- Millions of Indian asthma and COPD patients, many managing chronic illness on constrained budgets, face the prospect of either higher drug prices or reduced medication supply if the regulator cannot find a workable path forward.
When the chemistry that carries medicine into human lungs becomes scarce, the economics of compassion are forced into the open. Cipla, one of India's foremost pharmaceutical manufacturers, has appealed to the National Pharmaceuticals Pricing Authority to permit price increases on asthma and respiratory drugs, after the cost of propellant P227 — the invisible engine inside every metered dose inhaler — surged by roughly 300 percent due to supply shortages. The regulator now holds in its hands a question as old as public health itself: who bears the cost when the systems sustaining essential medicine begin to strain?
Cipla, headquartered in Mumbai and among India's most significant pharmaceutical producers, has formally asked the government to allow it to raise prices on asthma and respiratory medications. The trigger is a dramatic cost shock: propellant P227, a chemical compound central to how inhalers function, has become both scarce and expensive, with prices rising by approximately 300 percent in recent months.
The propellant is not a minor ingredient. In a metered dose inhaler — the handheld device most asthma patients rely on — it constitutes between 95 and 99 percent of the total contents. It generates the pressure that transforms active medication into a fine mist capable of reaching deep into the lungs, where it addresses the inflammation and constriction of asthma and COPD. Without it functioning correctly, the drug simply does not arrive where it is needed.
Cipla's letter to the National Pharmaceuticals Pricing Authority traces the shortage to a limited pool of global manufacturers capable of producing P227, itself a successor to chlorofluorocarbons that were phased out for environmental reasons. When supply contracted, prices climbed sharply — a 300 percent increase means production costs have roughly quadrupled.
The NPPA, which operates under the Ministry of Chemicals and Fertilisers, must now weigh two uncomfortable realities against each other. If it permits price increases, patients managing chronic respiratory illness on modest incomes may find their medications harder to afford. If it holds prices steady and manufacturers cannot recover costs, supply could contract further, creating a different kind of access crisis. The regulator's response will carry consequences well beyond one company's balance sheet, touching the daily lives of millions of Indians who depend on these medications to breathe.
Cipla, one of India's largest pharmaceutical manufacturers, has formally requested that the government allow it to raise prices on asthma and respiratory medications. The Mumbai-based company cited a stark reason: the cost of a critical ingredient used in these drugs has surged by roughly 300 percent in recent months, straining production economics to an unsustainable point.
The request, submitted to India's National Pharmaceuticals Pricing Authority in early September, zeroes in on a specific culprit: propellant P227, a chemical compound essential to how asthma inhalers actually work. Cipla explained in the letter that shortages from manufacturers have made this ingredient scarce and expensive, directly inflating what the company pays to produce the medications that millions of Indians depend on for breathing.
Understanding why this matters requires knowing what propellants do. In a metered dose inhaler—the handheld device asthma patients use—the propellant makes up between 95 and 99 percent of the contents. It creates the pressure needed to convert the active medication into a fine mist that travels deep into the lungs, where it can actually treat the inflammation and constriction that characterizes asthma and chronic obstructive pulmonary disease. Without the propellant working correctly, the drug never reaches where it needs to go. The propellant is not incidental; it is the delivery mechanism itself.
Cipla's letter describes the price movement as "astronomical." The company noted that after chlorofluorocarbons were phased out for environmental reasons, pharmaceutical manufacturers shifted to alternative propellants deemed safer for the environment and less toxic to humans. Propellant P227 became one of the two main options available. But when supply tightened and fewer manufacturers could produce it, prices climbed sharply—a 300 percent increase translates to production costs that have roughly quadrupled.
The company's formal appeal now sits with the National Pharmaceuticals Pricing Authority, the government body responsible for regulating drug prices in India and ensuring both manufacturer viability and patient access. The NPPA operates under the Department of Pharmaceuticals within the Ministry of Chemicals and Fertilisers. How the regulator responds will shape whether Cipla and other manufacturers can pass these costs to consumers, or whether they must absorb them and potentially reduce production or supply.
The stakes extend beyond one company's margins. Asthma affects millions of Indians across income levels, and respiratory diseases remain a significant public health burden. If prices rise substantially, patients already managing chronic conditions on fixed budgets may face harder choices about whether to refill prescriptions. If prices are held steady and manufacturers cannot recover costs, supply could tighten further. The NPPA's decision will have to weigh these competing pressures—the genuine cost shock Cipla describes against the real risk that price increases could push essential medications out of reach for vulnerable populations.
Notable Quotes
Due to shortage and unavailability from the manufacturers, its price has seen an increase of approximately over 300 percent which is gravely impacting our production cost— Cipla, in letter to NPPA dated September 2, 2021
Want the full story?
Read the original at News18 ↗
Politics & Governance